Michael Andreeff

64PUBLICATIONS

261CO-AUTHORS

Gene and molecular therapyHaematological tumoursApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markersRegenerative medicine (incl. stem cells)

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (64)

Sort by Publication Date:

|Jul 13, 2026

The novel hypomethylating agent NTX-301 reprograms epigenetic and Hippo signaling pathways and exhibits pre-clinical activity in venetoclax-resistant and TP53-mutant AML.

|Jul 06, 2026

Decreased TXNRD1 is associated with resistance to tagraxofusp in blastic plasmacytoid dendritic cell neoplasms, as seen in phase II.

|Jun 22, 2026

Investigational clinical trial agents versus conventional second salvage therapies in patients with relapsed/refractory acute myeloid leukemia.

|Jun 11, 2026

All-Oral Combination of Revumenib, Decitabine, and Venetoclax for Relapsed or Refractory AML (SAVE).

|Jun 01, 2026

TP53 deficiency in AML induces resistance to T-cell engagers through an immunosuppressive secretome.

|Apr 14, 2026

Integrated Analysis of Genomics, Molecular Responses, and Outcomes of CBF-AML with FLAG-Based Therapy on a Phase II Trial.

Jayastu Senapati, Hagop M Kantarjian, Edward Ayoub

Pageof 11

Frequent Collaborators

23 joint publications

Naval G Daver

18 joint publications

Courtney DiNardo

18 joint publications

Marina Y Konopleva

17 joint publications

Hagop M Kantarjian

17 joint publications

Gautam Borthakur

15 joint publications

Guillermo Garcia-Manero

14 joint publications

Sanam Loghavi

14 joint publications

Tapan M Kadia

12 joint publications

Ghayas Issa

12 joint publications

Bing Z Carter

Frequent Collaborators

23 joint publications

Naval G Daver

18 joint publications

Courtney DiNardo

18 joint publications

Marina Y Konopleva

17 joint publications

Hagop M Kantarjian